Search results
Showing 3181 to 3195 of 7684 results
Alcohol use: risk assessment for people with hypertension (IND196)
This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 12 months who have been screened for hazardous drinking using the FAST or AUDIT-C tool in the 3 months before or after the date of entry on the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved
This indicator covers the percentage of patients with heart failure on the register, who had a review in the preceding 12 months, including an assessment of functional capacity (using the New York Heart Association classification) and a review of medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM174
This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with a beta-blocker licensed for heart failure. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM173
This indicator covers the percentage of patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, who are currently treated with an ACE-I or ARB. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM172
This indicator covers the percentage of patients with a diagnosis of heart failure after (start date) which has been confirmed by an echocardiogram or by specialist assessment between 3 months before or 3 months after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM171
This indicator covers the percentage of patients with COPD on the register, who have had a review in the preceding 12 months, including a record of the number of exacerbations and an assessment of breathlessness using the Medical Research Council dyspnoea scale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM170
This indicator covers registering patients with a clinical diagnosis of COPD before (start date), and patients with a clinical diagnosis of COPD on or after (start date) whose diagnosis has been confirmed by a quality assured post bronchodilator spirometry FEV1/FVC ratio below 0.7 between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM169
This indicator covers the proportion of pregnant women who were smokers at the time of delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG32
This indicator covers the percentage of patients with asthma on the register aged 19 or under, in whom there is a record of smoking status (active or passive) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM168
This indicator covers the percentage of patients with asthma on the register from (start date) with a record of spirometry and 1 other objective test (FeNO or reversibility or variability) between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM166
This indicator covers the contractor establishing and maintaining a register of patients with asthma aged 5 or over. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM165
Diabetes: statins for primary prevention of CVD (40 years and over) (IND183)
This indicator covers the percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a cardiovascular disease risk score of less than 10% recorded in the preceding 3 years). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM162
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This indicator covers the percentage of patients with a diagnosis of type 2 diabetes and a recorded cardiovascular disease risk assessment score of 10% or more (without moderate or severe frailty), who are currently treated with a statin (unless there is a contraindication or statin therapy is declined). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM161
This indicator covers the percentage of patients aged between 25 and 84 years, with type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a full formal cardiovascular disease risk assessment in the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM160
This indicator covers the percentage of patients with diabetes with moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM158